SE0202608D0 - New sequences - Google Patents

New sequences

Info

Publication number
SE0202608D0
SE0202608D0 SE0202608A SE0202608A SE0202608D0 SE 0202608 D0 SE0202608 D0 SE 0202608D0 SE 0202608 A SE0202608 A SE 0202608A SE 0202608 A SE0202608 A SE 0202608A SE 0202608 D0 SE0202608 D0 SE 0202608D0
Authority
SE
Sweden
Prior art keywords
new sequences
agents
useful
ceta
pkc
Prior art date
Application number
SE0202608A
Other languages
Swedish (sv)
Inventor
Anneli Attersand
Staffan Lake
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Priority to SE0202608A priority Critical patent/SE0202608D0/en
Publication of SE0202608D0 publication Critical patent/SE0202608D0/en
Priority to AU2003256209A priority patent/AU2003256209A1/en
Priority to PCT/SE2003/001361 priority patent/WO2004022592A1/en

Links

Abstract

The invention relates to the use of the human Protein Kinase Ceta (PKC-eta) isoform, in methods for identification of pharmaceutically useful agents, in particular agents useful for the treatment of type 2 diabetes.
SE0202608A 2002-09-04 2002-09-04 New sequences SE0202608D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SE0202608A SE0202608D0 (en) 2002-09-04 2002-09-04 New sequences
AU2003256209A AU2003256209A1 (en) 2002-09-04 2003-09-03 Use of human protein kinase c-eta in methods for identification of pharmaceutically useful agents
PCT/SE2003/001361 WO2004022592A1 (en) 2002-09-04 2003-09-03 Use of human protein kinase c-eta in methods for identification of pharmaceutically useful agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0202608A SE0202608D0 (en) 2002-09-04 2002-09-04 New sequences

Publications (1)

Publication Number Publication Date
SE0202608D0 true SE0202608D0 (en) 2002-09-04

Family

ID=20288884

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0202608A SE0202608D0 (en) 2002-09-04 2002-09-04 New sequences

Country Status (3)

Country Link
AU (1) AU2003256209A1 (en)
SE (1) SE0202608D0 (en)
WO (1) WO2004022592A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007089546A (en) * 2005-09-30 2007-04-12 Univ Of Tokushima Rheumatoid arthritis susceptible gene and method for measuring risk of rheumatoid arthritis
WO2007123233A1 (en) 2006-04-25 2007-11-01 Kyushu University, National University Corporation Gene associated with arteriosclerotic disease, and use thereof
WO2018150430A1 (en) * 2017-02-19 2018-08-23 The National Institute for Biotechnology in the Negev Ltd. Peptide kinase inhibitors and methods of use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1490509A4 (en) * 2001-01-12 2005-06-01 Exelixis Inc Modulating insulin receptor signaling

Also Published As

Publication number Publication date
WO2004022592A1 (en) 2004-03-18
AU2003256209A1 (en) 2004-03-29

Similar Documents

Publication Publication Date Title
DE60327999D1 (en) AZOLYLAMINOAZINES AS INHIBITORS OF PROTEIN KINASES
ATE451376T1 (en) COMPOSITIONS SUITABLE AS INHIBITORS OF PROTEIN KINASES
DE60314603D1 (en) COMPOSITIONS NECESSARY AS PROTEIN KINASE INHIBITORS
ATE466580T1 (en) AZOLYLAMINOAZINE AS PROTEIN KINASE INHIBITORS
ATE468336T1 (en) AZOLYLAMINOAZINE AS PROTEIN KINASE INHIBITORS
DE602004014117D1 (en) THIAZOLE FOR USE AS INHIBITORS OF PROTEIN KINASES
UA85559C2 (en) Aminobenzophenone compounds
BR0116452A (en) Compound, pharmaceutical composition, use of a compound
DE602004021585D1 (en) 5,7-DIAMINOPYRAZOLOi4,3-D PYRIMIDINE FOR USE IN THE TREATMENT OF BLOOD HIGH PRESSURE
DE60314500D1 (en) DIAMINOPYRIMIDINE AND ITS USE AS ANGIOGENESEHEMMER
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
DK1368060T3 (en) HMGB1 protein inhibitors and / or antagonists for the treatment of vascular disease
YU9404A (en) Peptide-based multimeric targeted contrast agents
ATE450530T1 (en) COMPOSITIONS FOR USE AS PROTEIN KINASE INHIBITORS
MXPA05013977A (en) Methods and compositions for treating amyloid-related diseases.
BR0309665A (en) Treatment of alpha-galactosidase deficiency at
HK1062923A1 (en) Igf-binding protein-derived peptide
NO20055741L (en) New chemical compounds
DE602004012578D1 (en) PYROME COMPOSITIONS SUITED AS INHIBITORS OF C-MET
WO2003104425A3 (en) Novel stable anti-cd22 antibodies
CY1110130T1 (en) MORPHOLINE PRODUCTS FOR USE AS DOPAMINE AGONISTS IN THERAPEUTIC DISEASE Therapeutic Treatment I.A.
RS51138B (en) S-mirtazapine for the treatment of hot flush
SE0302304D0 (en) Novel compounds
ATE522230T1 (en) BIPHENYLE AS AN IMAGING AGENT IN ALZHEIMER'S DISEASE
NO20060781L (en) Use of soluble CD164 in inflammatory and / or autoimmune disorders